Gilead Sciences Inc   (GILD)
Other Ticker:  
Price: $67.3100 $-0.44 -0.649%
Day's High: $67.89 Week Perf: -1.19 %
Day's Low: $ 67.19 30 Day Perf: -11.36 %
Volume (M): 4,975 52 Wk High: $ 87.87
Volume (M$): $ 334,867 52 Wk Avg: $77.29
Open: $67.80 52 Wk Low: $67.19

 Market Capitalization (Millions $) 84,736
 Shares Outstanding (Millions) 1,259
 Employees 14,400
 Revenues (TTM) (Millions $) 27,116
 Net Income (TTM) (Millions $) 5,613
 Cash Flow (TTM) (Millions $) 673
 Capital Exp. (TTM) (Millions $) 585

Gilead Sciences Inc
Gilead Sciences,'Inc. is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. We have six products that are currently marketed in the U.S., all of which are also marketed in other countries worldwide. Our research and clinical programs are focused on anti-infectives, including antivirals and antifungals. We endeavor to grow our existing portfolio of products through proprietary clinical development programs, internal discovery programs and an active product acquisition and in-licensing strategy.

Our Products

''Viread is approved for sale and is sold in the U.S. by our U.S. commercial team for use in combination with other antiretroviral agents for the treatment of HIV infection. Viread is also sold internationally by our international commercial teams, including in the European Union and Australia.

''Emtriva is approved for sale and is sold in the U.S. by our U.S. commercial team for use in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also sold in the European Union by our international commercial teams. We are currently developing a fixed-dose combination of Viread and Emtriva.

''AmBisome is approved for sale and is sold in more than 45 countries for the treatment of life-threatening fungal infections and in some of these countries for prevention of such infections. We market AmBisome in the major countries of Europe and co-promote AmBisome in the U.S. with Fujisawa Healthcare,'Inc. ('Fujisawa').

''Hepsera is approved for sale and is sold in the U.S. by our U.S. commercial team for the treatment of chronic hepatitis B. Hepsera received marketing approval in the European Union in March'2003 and has been launched in 13 countries in the European Union. Additional launches in the other countries in the European Union and other parts of the world are expected to occur in 2004.

''Tamiflu is approved for sale and is sold by our corporate partner Hoffmann-La Roche ('Roche') in more than 60 countries, including the U.S. and the European Union, for the prevention and treatment of influenza, and in Japan, where it is approved for the treatment of influenza.

''Vistide is approved for sale and is sold in the U.S. by our U.S. commercial team, and by Gilead's ex-U.S. partner, Pfizer Inc. ('Pfizer') (formerly Pharmacia Corporation), in 25 countries for the treatment of cytomegalovirus ('CMV') retinitis in patients with AIDS.

''DaunoXome is approved for sale and has been sold in more than 20 countries for the treatment of AIDS-related Kaposi's sarcoma. It was sold in the U.S. by our U.S. commercial team and by independent distributors abroad. In December' 2003, we decided to discontinue selling this product.

Commercial Operations

We have U.S. and international commercial sales operations. We have marketing subsidiaries in the United Kingdom, Germany, Italy, Spain, France, Portugal, Greece and Australia. Our commercial teams promote and sell Viread, Emtriva, Hepsera and AmBisome in the U.S., Europe and Australia. AmBisome is also sold by Fujisawa in the U.S. and by Sumitomo in Japan. GSK will promote and sell Hepsera in Asia and South America. We sell Vistide in the U.S and our commercial partner, Pfizer, sells Vistide outside of the U.S. Our commercial partner, Roche, promotes and sells Tamiflu everywhere it is sold. Japan Tobacco Inc. (Japan Tobacco) will promote and sell Viread and Emtriva in Japan when approved by Japanese regulatory authorities.

Our commercial teams promote Viread, Emtriva and Hepsera through direct field contact with physicians, hospitals, clinics and other healthcare providers who are involved in the treatment of patients with HIV (for Viread) or chronic hepatitis B (for Hepsera). They also promote AmBisome to infectious disease specialists, hematologists, intensive care units, hospitals, home health care providers and cancer specialists.

The European commercial team is supported by medical, sales operations, marketing, financial, regulatory, legal affairs, manufacturing and human resources and information technology personnel located primarily in our European headquarters in Paris, France. The U.S. and Australian commercial teams are supported by our worldwide headquarters in Foster City, California. In some countries outside of the U.S., we have agreements with third-party distributors, including distributors in certain of the countries where we have marketing operations, to promote, sell and distribute Viread, Emtriva, Hepsera and AmBisome. These international distribution agreements generally provide that the distributor has the exclusive right to sell Viread, Emtriva and AmBisome in a particular country or several countries for a specified period of time.

Collaborative Relationships

As part of our business strategy, we establish collaborations with other companies to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring from other companies products or rights to products and technologies that are complementary to our business.

Archemix Corporation

In October'2001, we entered into an agreement with Archemix Corporation (Archemix). Under this agreement we granted Archemix an exclusive sublicense to the SELEX technology to identify aptamers, subject to the exclusion of all development areas as to which rights have not already been granted or forfeited. Our rights to the SELEX technology derive from a license to us from University License Equity Holdings,'Inc., ('ULEHI'), the successor to University Technology Corporation and its predecessor University Research Corporation.

Chiron Corporation

In August'2003, we entered into a non-exclusive licensing agreement with Chiron Corporation (Chiron) for the research, development and commercialization of small molecule therapeutics against selected hepatitis C virus (HCV) drug targets. Under the agreement, we received non-exclusive rights to Chiron's HCV technology for drug screening purposes. We expect this technology to assist us in our research and discovery effort to identify and develop potential HCV therapies. Under the terms of the agreement, we paid Chiron an up-front license fee and agreed to make milestone payments and royalty payments if a product is developed using the licensed technology.

EyeTech Pharmaceuticals

In March'2000, we entered into an agreement with EyeTech Pharmaceuticals,'Inc. (EyeTech) relating to a product named Macugen that it has developed for the treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME). We invented the compound upon which Macugen is based, NX 1838, using SELEX technology licensed to us from ULEHI.'

We then licensed NX 1838 to EyeTech who further developed it into Macugen. Under its license from us, EyeTech is required to pay us fees and milestone payments, as well as a percentage of any revenue they generate from worldwide sales of Macugen. In addition, EyeTech granted us warrants to purchase EyeTech preferred stock. Our agreement with EyeTech expires upon the later of ten'years after first commercial sale of any product developed, or the date the last patent expires under the agreement. EyeTech granted Pfizer a sublicense relating to Macugen in December'2002. In December'2002, in connection with this sublicense, we entered into a license with Pfizer on the same terms as contained in our agreement with EyeTech. In December'2003, we also entered into an agreement with EyeTech to supply Macugen to EyeTech for three years.


In 1991, we entered into an agreement granting Fujisawa the exclusive right to promote and sell AmBisome in Canada and the primary responsibility to promote and sell AmBisome in the U.S. with Gilead as a co-promoter. Fujisawa pays us approximately 17% of Fujisawa's net revenues from sales of AmBisome in the U.S. We reserved the right to promote and sell AmBisome in the rest of the world, and pay Fujisawa 4% of our net revenues for AmBisome sales in significant Asian markets, including Japan, Korea, Taiwan, China and India. We manufacture all AmBisome that is sold worldwide. We sell AmBisome to Fujisawa for sale in the U.S. at a price equal to our cost to manufacture the product, and for sale in Canada at a price equal to our cost to manufacture the product, plus a specified percentage. Our agreement with Fujisawa terminates when the last patent covering AmBisome in the U.S. or Japan expires.


In April'2002, we entered into a licensing agreement with GSK giving it exclusive rights to commercialize Hepsera solely for the treatment of chronic hepatitis B in Asia, Latin America and certain other territories. In addition to fees, milestone payments and other contract revenues, GSK is required to pay us a percentage of any revenue they generate from sales of Hepsera in the licensed territories. Under our agreement with GSK, we have entered into a clinical and commercial supply agreement with GSK under which we are required to supply them with their clinical and commercial requirements at our fully burdened cost to do so, subject to reasonable forecasting and ordering procedures. Our agreement with GSK expires on an individual country basis the later of patent expiration or ten years from first commercial sale in the particular country. In addition, GSK has the right to electively terminate the agreement on 12 months notice to Gilead, subject to a fee for elective termination under some circumstances early during the term of the agreement.

Japan Tobacco

In July'2003, we entered into a licensing agreement with Japan Tobacco under which Japan Tobacco obtained the rights to commercialize products in Gilead's HIV portfolio in Japan. The agreement includes Viread, Emtriva and a future co-formulation of the two products. We received an up-front fee and are entitled to receive milestone payments. Japan Tobacco also is required to make payments to us based on product sales in Japan. Japan Tobacco has submitted an application for Viread and expects to submit an application for Emtriva and a co-formulation of the two products to Japanese regulatory authorities this year. As contemplated by the license agreement, in December'2003 we completed a supply agreement with Japan Tobacco under which we will supply Japan Tobacco with Viread and Emtriva and a future co-formulation of the two products.

OSI Pharmaceuticals

In December'2001, we sold to OSI Pharmaceuticals (OSI) our pipeline of clinical stage oncology products and related intellectual property, as well as our Boulder, Colorado operations. In consideration for the assets, we received from OSI $130.0 million in cash and 924,984 shares of OSI common stock. Additionally, OSI is required to pay us up to an additional $30.0 million in either cash or a combination of cash and OSI common stock upon the achievement by OSI of certain milestones related to the development of NX 211, the most advanced of the oncology product candidates. Separately, under a manufacturing agreement with OSI, we have agreed to produce for OSI liposomal formulations of two products, including NX 211, at our manufacturing facility in San Dimas, California.


In 1996, we entered into an agreement with Pfizer (formerly Pharmacia Corporation) relating to Vistide. Under this agreement, Pfizer has the exclusive right to market and sell Vistide in all countries outside of the U.S., subject to payment to us of a percentage of net revenues. We are required to sell Pfizer bulk Vistide and to maintain the Vistide patents. Our agreement with Pfizer expires on an individual country basis upon patent expiration or ten'years from first commercial sale in countries where the product is not covered by a patent. In addition, Pfizer may terminate the agreement as a whole upon six'months notice or upon notice on an individual country basis, three'months before applying for marketing approval of a competitive product.


In 1996, we entered into a collaboration agreement with Roche granting Roche exclusive worldwide rights to Tamiflu, as well as other proprietary influenza neuraminidase inhibitors. As of December'31, 2003, we have received license fees and milestone payments from Roche totaling $48.7'million relating to the execution of this agreement and to regulatory filings and approvals for Tamiflu. Roche also funded all of the research and development costs for Tamiflu, including reimbursement to us of $28.1'million for the period from January'1, 1997 through December'31, 2001. Under the agreement, Roche is responsible for pricing, manufacturing, promoting and selling Tamiflu on a worldwide basis and pays us a percentage of its net revenues from sales of Tamiflu, subject to reduction for certain defined manufacturing costs. Our agreement with Roche terminates on an individual country basis on the later of patent expiration or ten years from first commercial sale in the particular country. In addition, Roche has the right to terminate the agreement in its entirety or an individual country basis prior to expiration at any time upon 12'months notice.


In 1996, we entered into an agreement with Sumitomo that gave Sumitomo the exclusive right to develop and market AmBisome in Japan. In addition to milestone payments, Sumitomo is required to pay us a percentage of any revenue they generate from Japanese sales of AmBisome. If AmBisome is approved for sale in Japan, we would manufacture AmBisome for sale by Sumitomo in Japan. The price that we would charge Sumitomo for the supply of AmBisome and the percentage of revenues that they would be required to pay to us would be determined by the price of AmBisome in Japan. Our agreement with Sumitomo terminates on the later of patent expiration in Japan or ten years from first commercial sale in Japan.

Viread and Emtriva.'The HIV competitive landscape is becoming more crowded and complicated as treatment trends continue to evolve. A growing number of anti-HIV drugs are currently sold or are in advance stages of clinical development. Of the 22 branded drugs available in the U.S., Zerit (stavudine, d4T) sold by Bristol-Myers Squibb (BMS) and the fixed combination products, Combivir (AZT and 3TC) and Trizivir (AZT, 3TC, ABC), both sold by GSK, represent the most direct competition for Viread. These companies are in the process of launching formulations of existing drugs now indicated by the FDA for once-daily oral dosing. These include GSK's 300 mg dose of Epivir (3TC) and BMS's new extended release formulation of Zerit. Other recently approved antiretroviral products include atazanivir (QD protease inhibitor from BMS) and Fuzeon (injectable integrase inhibitor from Roche/Trimeris). GSK has filed an application for approval of a once-daily dose of Ziagen (abacavir), as well as a new fixed dose combination of Ziagen and Epivir. Other companies competing in the HIV therapeutic category are Pfizer, Merck, Boehringer-Ingelheim and Abbott.

AmBisome.'AmBisome faces strong competition from several current and expected competitors. Current competitors include:

''conventional amphotericin B, made by BMS and numerous generic manufacturers;

''caspofungin, a product developed by Merck, which is marketed as Cancidas in the U.S. and as Caspofungin elsewhere;

''voriconazole, developed by Pfizer, which is marketed as Vfend; and

''other lipid-based amphotericin B products approved in the U.S. and throughout Europe, including Abelcet, sold by Enzon Corp. in the U.S., Canada and Japan and by Medeus Pharma Ltd. in Europe, and Amphotec, sold by InterMune Pharmaceuticals,' Inc.

Presently unapproved but expected competitors include a class of treatments called echinocandins, including Fujisawa's micafungin, which received marketing approval in Japan in October'2002 and is under review for regulatory approval in the U.S. and Canada, and anidulafungin, a Vircuron,'Inc. (formerly Versicor,' Inc.) product candidate, which is being evaluated in multiple late-stage clinical trials. Finally, Schering Plough is developing Noxafil (posaconazole), which is currently in Phase 3 trials.Competition from these current and expected competitors has eroded and is likely to continue to erode the revenues we receive from sales of AmBisome.

Hepsera.'Hepsera faces significant competition from existing therapies for treating patients who are infected with HBV. Most significantly:

''Epivir-HBV (lamivudine) was developed by GSK in collaboration with Shire Pharmaceuticals, and is sold in all major countries throughout North and South America, Europe, and Asia. It is an orally administered nucleoside analogue that inhibits HBV DNA polymerase.

''Intron-A (interferon alfa-2b) is sold by Schering Plough in major countries throughout North and South America, Europe, and Asia. Intron-A is an injectable drug with immunomodulatory effects.

Hepsera may also face competition from clinical-stage candidates, including Bristol-Myers Squibb's entecavir and Idenix's LdT, two oral nucleoside analogues currently in Phase 3 trials. Other competition will include Roche's Pegasys (pegylated interferon alfa-2a), which is currently being studied for chronic hepatitis B.

Tamiflu.'Tamiflu competes with Relenza, an anti-flu drug that is sold by GSK. Relenza is a neuraminidase inhibitor that is delivered as an orally-inhaled dry powder.

Vistide.'Vistidecompetes with a number of drugs that also treat CMV retinitis, including ganciclovir, sold in intravenous and oral formulations by Roche and as an ocular implant by Bausch'& Lomb Incorporated; valganciclovir, also marketed by Roche; foscarnet, an intravenous drug sold by AstraZeneca; and, formivirsen, a drug injected directly into the eye sold by CibaVision.

A number of companies are pursuing the development of technologies competitive with our research programs. These competing companies include specialized pharmaceutical firms and large pharmaceutical companies acting either independently or together with biopharmaceutical companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection and may establish collaborative arrangements for competitive products and programs.

   Company Address: 333 Lakeside Drive Foster City 94404 CA
   Company Phone Number: 574-3000   Stock Exchange / Ticker: NASDAQ GILD

Customers Net Income fell by GILD's Customers Net Profit Margin fell to

-7.53 %

2.15 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV   -3.84%    
ABT   -1.76%    
BMY   -4.04%    
JNJ   -3.83%    
MRK   -1.33%    
PFE   -2.39%    
• View Complete Report

Gilead Sciences Inc

Gilead Sciences Inc Faces -11.97% Deterioration in EPS in October to December 31, 2023 Financial Period

As a financial analyst covering the biotechnology and pharmaceutical industry, the recent financial results reported by Gilead Sciences Inc have certainly raised some concerns. The company's income fell by -11.97% to $1.14 per share, and revenue decreased by -3.722% to $7.11 billion in the October to December 31, 2023 financial span. These numbers are disappointing, especially when compared to the industry average which saw a top-line gain of 13.28% in the fourth quarter of 2023.
Furthermore, Gilead Sciences Inc's profitability took a hit with operating margin decreasing to 22.66% and net margin shrinking to 19.92%. The increase in inventories to $1,787.0 million and the decline in accounts receivable to $4,660.0 million indicate potential issues with demand and cash flow within the company.


Kite and Arcellx Forge Powerful Alliance to Revolutionize Multiple Myeloma Treatment

Published Wed, Nov 15 2023 11:00 AM UTC

Kite and Arcellx Strengthen Partnership, Expanding Potential for Advanced Multiple Myeloma Treatment
In an exciting development within the biopharmaceutical industry, Kite, a subsidiary of Gilead Sciences, and Arcellx announced the expansion of their already fruitful collaboration. This strategic partnership, originally established in December 2022, has now taken a signi...

Gilead Sciences Inc

Gilead Sciences Defies Industry Challenges, Surges 21.83% in Q3 2023 Earnings Season with Strong Profits

Gilead Sciences Inc has once again defied the odds in the Biotechnology & Pharmaceuticals industry, reporting impressive financial results in the third quarter of 2023 earnings season. Despite the challenges faced by its contemporaries, Gilead Sciences Inc experienced a double-digit income advance on moderate revenue improvement.
The company's income saw a remarkable increase of 21.83%, reaching $1.73 per share compared to the previous reporting season. This substantial growth in earnings per share showcases the company's strong performance and ability to generate significant profits.
Furthermore, Gilead Sciences Inc managed to achieve a slight increase in revenue by 0.128%, reaching $7.05 billion. Although the growth may appear modest, it is crucial to note that this revenue surge is in contrast to the top-line demise witnessed by other companies in the same sector. Gilead Sciences Inc's ability to buck the trend and achieve revenue growth is a testament to its robust business model and effective strategies.

Gilead Sciences Inc

Gilead Sciences Inc Reports Boost in Revenue but Dip in Profits for Q2 2023

The biotechnology and pharmaceutical industry is a highly dynamic sector that consistently presents investors with numerous opportunities and challenges. One of the notable companies in this industry, Gilead Sciences Inc, recently reported its financial results for the period April to June 30, 2023. These results revealed some contradictory numbers that paint an intriguing picture of the company's performance during this period.
Revenue Growth Amid Declining Profits
Gilead Sciences Inc experienced a 5.415% increase in revenue, reaching $6.60 billion in the April to June 2023 quarter compared to $6.26 billion during the same period the previous year. This growth demonstrates the company's ability to generate more sales and highlights the demand for its products.

Gilead Sciences Inc

Gilead Sciences Inc's EPS Surges by 3900% in Q1 2023, Despite Revenue Decline

Investors should exercise caution when considering investment opportunities in Gilead Sciences Inc, based on the company's recent first quarter results. While the return on equity of 26.56% is below the company's average return of 35.6%, it is an improvement from the previous quarter. In addition, the company's revenue has declined year on year, which could further impact profitability.
It is important to note that Gilead Sciences Inc still remains competitive within the Biotechnology & Pharmaceuticals industry, with only one company having a higher return on equity. However, investors should carefully consider the company's overall ranking, which has improved to 613 from the previous quarter's ranking of 941. This suggests that the company is making strides, but it still has a way to go before it can be considered among the industry leaders.


Gilead Sciences Inc's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
HIV products Total
 Segment     of total Revenue
 Segment     of total Revenue
Other products
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Complera Eviplera
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Gilead Sciences Inc announced annual revenue outlook on

Earnings Outlook
Gilead Sciences Inc does not provide earnings estimates.

Geographic Revenue Dispersion
United States
Other European countries
Other countries


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com